Evaluación de efectividad y seguridad de everolimus más ciclosporina y esteroides o everolimus más tacrolimus y esteroide comparado con ciclosporina más micofenolato y esteroides, tacrolimus más micofenolato y esteroides, sirolimus con micofenolato y esteroides, en pacientes receptores de trasplante de riñón, hígado y corazón

Agudelo Berruecos, Yuli; Vanegas Escamilla, Egdda Patricia; Arias Barrera, Carlos Andrés; González, Natalia; García, Paola; Arroyave, Mady; Delgado, María Inés; Eliecer García, Jorge.
Bogotá; IETS; dic. 2014. 70 p. tab, ilus.
Monografía en Español | BRISA, LILACS | ID: biblio-847226

Documentos relacionados

  1. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
  2. Immunosuppression for lung transplantation: evidence to date.
  3. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
  4. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
  5. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.
  6. Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation.
  7. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
  8. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
  9. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
  10. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.